ADA and immunodeficiency disease: However, until 2000 there were indications of the reliability of these therapies in humans, after arduous attempts to improve the technique for the treatment of severe combined adenosine deaminase immunodeficiency (ADA-SCID) (Espinosa and Hernández-Hernández, 2020).